Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches

Abstract

Inflammatory bowel disease (IBD) is a complex heterogeneous disorder defined by recurring chronic inflammation of the gastrointestinal tract, attributed to a combination of factors including genetic susceptibility, altered immune response, a shift in microbial composition/microbial insults (infection/exposure), and environmental influences. Therapeutics generally used to treat IBD mainly focus on the immune response and include non-specific anti-inflammatory and immunosuppressive therapeutics and targeted therapeutics aimed at specific components of the immune system. Other therapies include exclusive enteral nutrition and emerging stem cell therapies. However, in recent years, scientists have begun to examine the interplay between these therapeutics and the gut microbiome, and we present this information here. Many of these therapeutics are associated with alterations to gut microbiome composition and functionality, often driving it toward a “healthier profile” and preclinical studies have revealed that such alterations can play an important role in therapeutic efficacy. The gut microbiome can also improve or hinder IBD therapeutic efficacy or generate undesirable metabolites. For certain IBD therapeutics, the microbiome composition, particularly before treatment, may serve as a biomarker of therapeutic efficacy. Utilising this information and manipulating the interactions between the gut microbiome and IBD therapeutics may enhance treatment outcomes in the future and bring about new opportunities for personalised, precision medicine.

Keywords

Inflammatory bowel disease / gut microbiome / IBD therapeutics / anti-inflammatory therapies / immunosuppressive therapies / responders / non-responders

References

[1] Gohil K.Ulcerative colitis and Crohn’s disease.P T2014;39:576-7. PMCID:PMC4123809

[2] Baumgart DC.Crohn’s disease.Lancet2012;380:1590-605

[3] Yu YR.Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes.Semin Pediatr Surg2017;26:349-55

[4] Wang R,Liu S.Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019.BMJ Open2023;13:e065186 PMCID:PMC10069527

[5] Ng SC,Hamidi N.Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.Lancet2017;390:2769-78

[6] Aldars-García L,Gisbert JP.Systematic review: the gut microbiome and its potential clinical application in inflammatory bowel disease.Microorganisms2021;9:977 PMCID:PMC8147118

[7] Sokol H,Aschard H.Fungal microbiota dysbiosis in IBD.Gut2017;66:1039-48 PMCID:PMC5532459

[8] Venegas DP,Landskron G.Corrigendum: short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases.Front Immunol2019;10:1486 PMCID:PMC6611342

[9] Sonnenburg ED.Starving our microbial self: the deleterious consequences of a diet deficient in microbiota-accessible carbohydrates.Cell Metab2014;20:779-86 PMCID:PMC4896489

[10] Roediger WE.Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man.Gut1980;21:793-8 PMCID:PMC1419533

[11] Couto MR,Magro F.Microbiota-derived butyrate regulates intestinal inflammation: focus on inflammatory bowel disease.Pharmacol Res2020;159:104947

[12] De Vadder F,Goncalves D.Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits.Cell2014;156:84-96

[13] Wu W,Chen F.Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43.Mucosal Immunol2017;10:946-56 PMCID:PMC5471141

[14] Ramírez-Pérez O,Chinchilla-López P.The role of the gut microbiota in bile acid metabolism.Ann Hepatol2017;16:S21-6

[15] Duboc H,Rainteau D.Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases.Gut2013;62:531-9

[16] Sinha SR,Nguyen LP.Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation.Cell Host Microbe2020;27:659-70.e5 PMCID:PMC8172352

[17] Singh S,Binion DG.AGA technical review on the management of mild-to-moderate ulcerative colitis.Gastroenterology2019;156:769-808.e29 PMCID:PMC6858923

[18] Das KM.Current medical therapy of inflammatory bowel disease.World J Gastroenterol2000;6:483-9 PMCID:PMC4723544

[19] Das KM,McManus JPA.Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.N Engl J Med1973;289:491-5

[20] Ye B.Mesalazine preparations for the treatment of ulcerative colitis: are all created equal?.World J Gastrointest Pharmacol Ther2015;6:137-44 PMCID:PMC4635154

[21] Kumar M,Roy CK,Malik A.Formulation development and evaluation of colon targeted beads of mesalamine.J Drug Des Res2018;5:1067Available from: https://www.researchgate.net/profile/Anuj-Malik-2/publication/324888491_Formulation_Development_and_Evaluation_of_Colon_Targeted_Beads_of_Mesalamine/links/5ae93d3745851588dd8174e5/Formulation-Development-and-Evaluation-of-Colon-Targeted-Beads-of-Mesalamine. [Last accessed on 25 Sep 2023]

[22] Bayan MF.Recent advances in mesalamine colonic delivery systems.Futur J Pharm Sci2020;6:1-7

[23] Rousseaux C,Dubuquoy L.Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ.J Exp Med2005;201:1205-15 PMCID:PMC2213148

[24] Nielsen OH.Drug insight: aminosalicylates for the treatment of IBD.Nat Clin Pract Gastroenterol Hepatol2007;4:160-70

[25] Braccia DJ,Weiss A.Gut microbiome-wide search for bacterial azoreductases reveals potentially uncharacterized azoreductases encoded in the human gut microbiome.Drug Metab Dispos2023;51:142-53

[26] Simpson JB,Carry BS,Patel S.Diverse but desolate landscape of gut microbial azoreductases: a rationale for idiopathic IBD drug response.Gut Microbes2023;15:2203963 PMCID:PMC10132220

[27] Sousa T,Zann V,Abrahamsson B.On the colonic bacterial metabolism of azo-bonded prodrugsof 5-aminosalicylic acid.J Pharm Sci2014;103:3171-5

[28] van Hogezand RA, Kennis HM, van Schaik A, Koopman JP, van Hees PAM, van Tongeren JHM. Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditions.Eur J Clin Pharmacol1992;43:189-92

[29] Deloménie C,Longuemaux S.Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid.J Bacteriol2001;183:3417-27 PMCID:PMC99640

[30] Allgayer H,Kruis W.Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease.Gastroenterology1989;97:38-41

[31] Mehta RS,Zhang Y.Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease.Nat Med2023;29:700-9

[32] Sandberg-Gertzen H,Sundberg-Gillå B.In vitro effects of sulphasalazine, azodisal sodium, and their metabolites on Clostridium difficile and some other faecal bacteria.Scand J Gastroenterol1985;20:607-12

[33] Liu F,Riordan SM.Azathioprine, mercaptopurine, and 5-aminosalicylic acid affect the growth of IBD-associated Campylobacter species and other enteric microbes.Front Microbiol2017;8:527 PMCID:PMC5372805

[34] Zhang L,Grimm MC,Day AS.Campylobacter concisus and inflammatory bowel disease.World J Gastroenterol2014;20:1259-67 PMCID:PMC3921508

[35] Zhang L.Oral Campylobacter species: initiators of a subgroup of inflammatory bowel disease?.World J Gastroenterol2015;21:9239-44 PMCID:PMC4541376

[36] Schwartz AG,Saxon A.Sulfasalazine-induced exacerbation of ulcerative colitis.N Engl J Med1982;306:409-12

[37] Zhang S,Dogan B,Simpson KW.5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity.J Antibiot2018;71:950-61

[38] Kaufman J,Surette MG,Rioux KP.Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression.Inflamm Bowel Dis2009;15:985-96

[39] Dahl JU,Bazopoulou D.The anti-inflammatory drug mesalamine targets bacterial polyphosphate accumulation.Nat Microbiol2017;2:16267 PMCID:PMC5514548

[40] Rao NN,Kornberg A.Inorganic polyphosphate: essential for growth and survival.Annu Rev Biochem2009;78:605-47

[41] Gray MJ,Wagner NO.Polyphosphate is a primordial chaperone.Mol Cell2014;53:689-99 PMCID:PMC3996911

[42] Roewe J,Strueve M.Bacterial polyphosphates interfere with the innate host defense to infection.Nat Commun2020;11:4035 PMCID:PMC7423913

[43] Zheng H,Li Y.Modulation of gut microbiome composition and function in experimental colitis treated with sulfasalazine.Front Microbiol2017;8:1703 PMCID:PMC5594074

[44] Cevallos SA,Velazquez EM.5-aminosalicylic acid ameliorates colitis and checks dysbiotic Escherichia coli expansion by activating PPAR-γ signaling in the intestinal epithelium.mBio2021;12:e03227-20 PMCID:PMC7845635

[45] Huang Y,Xiao H,Yang G.Mesalamine-mediated amelioration of experimental colitis in piglets involves gut microbiota modulation and intestinal immune cell infiltration.Front Immunol2022;13:883682 PMCID:PMC9309220

[46] Andrews CN,Kaufman J,Surette MG.Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome.Aliment Pharmacol Ther2011;34:374-83

[47] Olaisen M,Flatberg A.Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.Aliment Pharmacol Ther2019;49:1301-13 PMCID:PMC6593792

[48] Jun X,Yang S.Alteration of fungal microbiota after 5-ASA treatment in UC patients.Inflamm Bowel Dis2020;26:380-90

[49] Targownik LE,Bernstein CN.Combined biologic and immunomodulatory therapy is superior to monotherapy for decreasing the risk of inflammatory bowel disease-related complications.J Crohns Colitis2020;14:1354-63

[50] Crohn’s and Colitis, UK. Methotrexate. 2019. Available from: https://crohnsandcolitis.org.uk/media/4qinwgmh/methotrexate-pdf.pdf. [Last accessed on 25 Sep 2023]

[51] Crouwel F,de Boer NK.Gut microbiota-driven drug metabolism in inflammatory bowel disease.J Crohns Colitis2020;15:307-15 PMCID:PMC7904070

[52] Nayak RR,Deshpande I.Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation.Cell Host Microbe2021;29:362-77.e11 PMCID:PMC7954989

[53] AlAmeel T,Raine T.Methotrexate in inflammatory bowel disease: a primer for gastroenterologists.Saudi J Gastroenterol2022;28:250-60 PMCID:PMC9408741

[54] Dervieux T,Kremer J.Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis.Rheumatology2010;49:2337-45

[55] Sayers E,Carding SR.Drug-microbiota interactions and treatment response: Relevance to rheumatoid arthritis.AIMS Microbiol2018;4:642-54 PMCID:PMC6613334

[56] Cronstein BN.Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.Nat Rev Rheumatol2017;13:41-51 PMCID:PMC5173391

[57] Nayak RR,Fischbach M. Methotrexate is an antibacterial drug metabolized by human gut bacteria. 2016. p. 1204. Available from: https://acrabstracts.org/abstract/methotrexate-is-an-antibacterial-drug-metabolized-by-human-gut-bacteria/. [Last accessed on 25 Sep 2023]

[58] Levy CC.The enzymatic hydrolysis of methotrexate and folic acid.J Biol Chem1967;242:2933-8.

[59] Letertre MPM,Wolfer K.A two-way interaction between methotrexate and the gut microbiota of male sprague-dawley rats.J Proteome Res2020;19:3326-39 PMCID:PMC7426014

[60] Mccullough JL,Bertino JR.Purification and properties of carboxypeptidase G 1.J Biol Chem1971;246:7207-13

[61] Rattu MA,Lee JM,Marzella N.Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity.P T2013;38:732-44. PMCID:PMC3875266

[62] Larimer CM,Pitstick LD.Comparison of substrate specificity of Escherichia coli p-aminobenzoyl-glutamate hydrolase with Pseudomonas carboxypeptidase G.Adv Enzyme Res2014;2:39-48 PMCID:PMC5082436

[63] Shin YS,Stokstad EL.The metabolism of methotrexate in Lactobacillus casei and rat liver and the influence of methotrexate on metabolism of folic acid.J Biol Chem1974;249:5772-7.

[64] Liu J,Bolstad ESD,Anderson AC.Towards new antifolates targeting eukaryotic opportunistic infections.Eukaryot Cell2009;8:483-6 PMCID:PMC2669212

[65] Greenstein RJ,Haroutunian V,Brown ST.On the action of methotrexate and 6-mercaptopurine on M. avium subspecies paratuberculosis.PLoS One2007;2:e161 PMCID:PMC1779805

[66] Pierce ES.Could Mycobacterium avium subspecies paratuberculosis cause Crohn’s disease, ulcerative colitis…and colorectal cancer?.Infect Agent Cancer2018;13:1 PMCID:PMC5753485

[67] Zhou B,Wang P.Induction and amelioration of methotrexate-induced gastrointestinal toxicity are related to immune response and gut microbiota.EBioMedicine2018;33:122-33 PMCID:PMC6085585

[68] R R,Menon T,Machani S.An unusual presentation of a patient with low-dose methotrexate causing colitis and pancytopenia.Cureus2022;14:e33062 PMCID:PMC9883061

[69] Kopytek SJ,Knapp GS.Resistance to methotrexate due to AcrAB-dependent export from Escherichia coli.Antimicrob Agents Chemother2000;44:3210-2 PMCID:PMC101636

[70] Guðmundsdóttir JS,Koumans CIM.The chemotherapeutic drug methotrexate selects for antibiotic resistance.EBioMedicine2021;74:103742 PMCID:PMC8671861

[71] Chourpiliadis C. Physiology, glucocorticoids. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560897/. [Last accessed on 25 Sep 2023]

[72] Timmermans S,Libert C.A general introduction to glucocorticoid biology.Front Immunol2019;10:1545 PMCID:PMC6621919

[73] Bruscoli S,Riccardi C.Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice.Front Immunol2021;12:691480 PMCID:PMC8209469

[74] Franzin M,Lucafò M,Stocco G.Microbiota and drug response in inflammatory bowel disease.Pathogens2021;10:211 PMCID:PMC7919657

[75] Dorrington AM,Parkes GC,Pollok RC.The historical role and contemporary use of corticosteroids in inflammatory bowel disease.J Crohns Colitis2020;14:1316-29

[76] Torres J,Doherty G.ECCO guidelines on therapeutics in Crohn’s disease: medical treatment.J Crohns Colitis2020;14:4-22

[77] Matsuoka K,Ueno F.Evidence-based clinical practice guidelines for inflammatory bowel disease.J Gastroenterol2018;53:305-53 PMCID:PMC5847182

[78] Al-Sanea MM,Omar FA.Biotransformation studies of prednisone using human intestinal bacteria part II: anaerobic incubation and docking studies.J Enzyme Inhib Med Chem2009;24:1211-9

[79] Yadav V,Merchant HA.Colonic bacterial metabolism of corticosteroids.Int J Pharm2013;457:268-74

[80] Vertzoni M,van der Mey D,Reppas C.Evaluating the clinical importance of bacterial degradation of therapeutic agents in the lower intestine of adults using adult fecal material.Eur J Pharm Sci2018;125:142-50

[81] Tannergren C,Lennernäs H.Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment.Mol Pharm2009;6:60-73

[82] Zimmermann M,Wegmann R.Mapping human microbiome drug metabolism by gut bacteria and their genes.Nature2019;570:462-7 PMCID:PMC6597290

[83] Ridlon JM,Alves JMP.Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens.J Lipid Res2013;54:2437-49 PMCID:PMC3735941

[84] Cerone-McLernon AM,Mosbach EH.Side-chain cleavage of cortisol by fecal flora.Biochim Biophys Acta1981;666:341-7

[85] Krafft AE,Bokkenheuser VD.Cofactor requirements of steroid-17-20-desmolase and 20 α-hydroxysteroid dehydrogenase activities in cell extracts of Clostridium scindens.J Steroid Biochem1987;28:49-54

[86] Ly LK,Paul HM.Bacterial steroid-17,20-desmolase is a taxonomically rare enzymatic pathway that converts prednisone to 1,4-androstanediene-3,11,17-trione, a metabolite that causes proliferation of prostate cancer cells.J Steroid Biochem Mol Biol2020;199:105567 PMCID:PMC7333170

[87] Huang EY,Leone VA.Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases.Inflamm Bowel Dis2015;21:963-72 PMCID:PMC4402247

[88] Tourret J,Dion S,Denamur E.Immunosuppressive treatment alters secretion of ileal antimicrobial peptides and gut microbiota, and favors subsequent colonization by uropathogenic Escherichia coli.Transplantation2017;101:74-82

[89] Igarashi H,Ohno K,Odamaki T.Effect of oral administration of metronidazole or prednisolone on fecal microbiota in dogs.PLoS One2014;9:e107909 PMCID:PMC4168260

[90] Atherly T,White R.Glucocorticoid and dietary effects on mucosal microbiota in canine inflammatory bowel disease.PLoS One2019;14:e0226780 PMCID:PMC6936794

[91] Krogsgaard LR, Munck LK, Bytzer P, Wildt S. An altered composition of the microbiome in microscopic colitis is driven towards the composition in healthy controls by treatment with budesonide.Scand J Gastroenterol2019;54:446-52

[92] Rusnak F.Calcineurin: form and function.Physiol Rev2000;80:1483-521

[93] Guada M,Kumar MNVR,Dios-Viéitez MC.Reformulating cyclosporine A (CsA): more than just a life cycle management strategy.J Control Release2016;225:269-82

[94] Evirgen S,Akyüz F.Cyclosporine therapy as a rescue treatment in steroid refractory acute severe ulcerative colitis: a real life data from a tertiary center.Turk J Gastroenterol2022;33:463-9 PMCID:PMC9317765

[95] D'Haens G,Geboes K.Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis.Gastroenterology2001;120:1323-9

[96] García-López S,Pérez-Gisbert J.Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review.Gastroenterol Hepatol2005;28:607-14

[97] Laharie D,Branche J.Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.Gut2018;67:237-43

[98] Wu B,Ran Z.Tacrolimus therapy in steroid-refractory ulcerative colitis: a review.Inflamm Bowel Dis2020;26:24-32

[99] Wang J,Smart AL,Basit AW.Stability of peptide drugs in the colon.Eur J Pharm Sci2015;78:31-6

[100] Guo Y,Won KJ.Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites.Drug Metab Dispos2019;47:194-202 PMCID:PMC6367689

[101] Zhang Z,Tang H.Immunosuppressive effect of the gut microbiome altered by high-dose tacrolimus in mice.Am J Transplant2018;18:1646-56

[102] Lv W,He T.Combination of Lactobacillus plantarum improves the effects of tacrolimus on colitis in a mouse model.Front Cell Infect Microbiol2023;13:1130820 PMCID:PMC10040537

[103] Jiang JW,Lu HF.Optimal immunosuppressor induces stable gut microbiota after liver transplantation.World J Gastroenterol2018;24:3871-83 PMCID:PMC6141331

[104] Toral M,Rodríguez-Nogales A.Lactobacillus fermentum improves tacrolimus-induced hypertension by restoring vascular redox state and improving eNOS coupling.Mol Nutr Food Res2018;62:1800033

[105] Ekberg H,Kaplan B.Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation.Transplantation2011;92:82-7

[106] Kawakami K,Murano M.Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis.World J Gastroenterol2015;21:1880-6 PMCID:PMC4323466

[107] Zaza G,Felis G,Torriani S.Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: comparison between an everolimus- and a standard tacrolimus-based regimen.PLoS One2017;12:e0178228 PMCID:PMC5443527

[108] O’Reilly C,Cotter PD.Encapsulated cyclosporine does not change the composition of the human microbiota when assessed ex vivo and in vivo.J Med Microbiol2020;69:854-63 PMCID:PMC7451034

[109] Lin CMA,Isaacs JD.Basic mechanisms of JAK inhibition.Mediterr J Rheumatol2020;31:100-4 PMCID:PMC7361186

[110] Liu E,Nigam G.Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going.Drugs Context2022;11:1-17 PMCID:PMC9007061

[111] Han Q,Zou M.Anemoside B4 protects against chronic relapsing colitis in mice by modulating inflammatory response, colonic transcriptome and the gut microbiota.Phytomedicine2022;106:154416

[112] Texler B,Reinstadler V.Tofacitinib-induced modulation of intestinal adaptive and innate immunity and factors driving cellular and systemic pharmacokinetics.Cell Mol Gastroenterol Hepatol2022;13:383-404 PMCID:PMC8688178

[113] Hablot J,Lavelle A.Tofacitinib treatment alters mucosal immunity and gut microbiota during experimental arthritis.Clin Transl Med2020;10:e163 PMCID:PMC7510778

[114] Jang DI,Shin HY.The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics.Int J Mol Sci2021;22:2719 PMCID:PMC7962638

[115] Murch SH,Walker-Smith JA.Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.Gut1993;34:1705-9 PMCID:PMC1374467

[116] Reinecker HC,Witthoeft T.Enhand secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn’s disease.Clin Exp Immunol1993;94:174-81 PMCID:PMC1534387

[117] Levin AD,van den Brink GR.Mechanism of action of anti-TNF therapy in inflammatory bowel disease.J Crohns Colitis2016;10:989-97

[118] Peyrin-Biroulet L.Review article: remission rates achievable by current therapies for inflammatory bowel disease.Aliment Pharmacol Ther2011;33:870-9

[119] Atiqi S,Loeff FC,Wolbink GJ.Immunogenicity of TNF-inhibitors.Front Immunol2020;11:312 PMCID:PMC7055461

[120] Park J.Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α.Korean J Intern Med2022;37:895-905 PMCID:PMC9449200

[121] Papamichael K,Rutgeerts P.Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.Inflamm Bowel Dis2015;21:182-97

[122] Sidorin EV.IgG-binding proteins of bacteria.Biochemistry2011;76:295-308

[123] Brezski RJ.Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?.mAbs2010;2:212-20 PMCID:PMC2881249

[124] Moussata D,Gloeckner A.Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo.Gut2011;60:26-33 PMCID:PMC3002833

[125] Deveuve Q,Barrault B.The proteolytic cleavage of therapeutic monoclonal antibody hinge region: more than a matter of subclass.Front Immunol2020;11:168 PMCID:PMC7026020

[126] Biancheri P,Di Sabatino A.Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.Gastroenterology2015;149:1564-74.e3

[127] Wang Y,Ghozlane A.Characteristics of faecal microbiota in paediatric Crohn’s disease and their dynamic changes during infliximab therapy.J Crohns Colitis2018;12:337-46

[128] Zhuang X,Feng R.Fecal microbiota alterations associated with clinical and endoscopic response to infliximab therapy in Crohn’s disease.Inflamm Bowel Dis2020;26:1636-47

[129] Ditto MC,Landolfi G.Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis.RMD Open2021;7:e001755 PMCID:PMC8422478

[130] Ribaldone DG,Abdulle A.Adalimumab therapy improves intestinal dysbiosis in Crohn’s disease.J Clin Med2019;8:1646 PMCID:PMC6832711

[131] Effenberger M,Waschina S.Microbial butyrate synthesis indicates therapeutic efficacy of azathioprine in IBD patients.J Crohns Colitis2021;15:88-98

[132] Seong G,Joung JG.Changes in the intestinal microbiota of patients with inflammatory bowel disease with clinical remission during an 8-week infliximab infusion cycle.Microorganisms2020;8:874 PMCID:PMC7356282

[133] Magnusson MK,Sapnara M.Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition.J Crohns Colitis2016;10:943-52

[134] Monast CS,Li K,Brodmerkel C.Su1217 the role of the microbiome in clinical response to golimumab in ulcerative colitis.Gastroenterology2016;150:S498

[135] Bazin T,Barnetche T.Microbiota composition may predict anti-tnf alpha response in spondyloarthritis patients: an exploratory study.Sci Rep2018;8:5446 PMCID:PMC5882885

[136] Aden K,Waschina S.Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel diseases.Gastroenterology2019;157:1279-92.e11

[137] Alatawi H,Saadah OI.Attributes of intestinal microbiota composition and their correlation with clinical primary non-response to anti-TNF-α agents in inflammatory bowel disease patients.Bosn J Basic Med Sci2022;22:412-26 PMCID:PMC9162754

[138] Ventin-Holmberg R,Saqib S.Bacterial and fungal profiles as markers of infliximab drug response in inflammatory bowel disease.J Crohns Colitis2021;15:1019-31

[139] Lee JWJ,Hogstrom L.Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease.Cell Host Microbe2021;29:1294-304.e4 PMCID:PMC8366279

[140] Yilmaz B,Øyås O.Microbial network disturbances in relapsing refractory Crohn’s disease.Nat Med2019;25:323-36

[141] Wang Y,Zhang X.Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease.Gut Microbes2021;13:1-18 PMCID:PMC7808429

[142] Busquets D,Amoedo J.RAID prediction: pilot study of fecal microbial signature with capacity to predict response to anti-TNF treatment.Inflamm Bowel Dis2021;27:S63-6

[143] Estevinho MM,Correia L.Features of fecal and colon microbiomes associate with responses to biologic therapies for inflammatory bowel diseases: a systematic review.Clin Gastroenterol Hepatol2020;18:1054-69

[144] Wyant T,Abhyankar B.An overview of the mechanism of action of the monoclonal antibody vedolizumab.J Crohns Colitis2016;10:1437-44

[145] Rogler G.Mechanism of action of vedolizumab: do we really understand it?.Gut2019;68:4-5

[146] Bhandari R,Kareem R.Efficacy and safety of vedolizumab in management of moderate to severe ulcerative colitis: a systematic review.Cureus2021;13:e17729 PMCID:PMC8491799

[147] Ananthakrishnan AN,Yajnik V.Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases.Cell Host Microbe2017;21:603-10.e3 PMCID:PMC5705050

[148] Scott KP,Chassard C.Substrate-driven gene expression in Roseburia inulinivorans: importance of inducible enzymes in the utilization of inulin and starch.Proc Natl Acad Sci U S A2011;108:4672-9 PMCID:PMC3063597

[149] Ihekweazu FD,Queliza K.Bacteroides ovatus ATCC 8483 monotherapy is superior to traditional fecal transplant and multi-strain bacteriotherapy in a murine colitis model.Gut Microbes2019;10:504-20 PMCID:PMC6748610

[150] Moschen AR,Raine T.IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.Nat Rev Gastroenterol Hepatol2019;16:185-96

[151] Scribano ML,Neri B.Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy.Therap Adv Gastroenterol2022;15:17562848211072412 PMCID:PMC8848093

[152] Doherty MK,Koumpouras C.Fecal microbiota signatures are associated with response to ustekinumab therapy among Crohn’s disease patients.mBio2018;9:e02120-17 PMCID:PMC5850325

[153] Yeh NL,Tsai TF.Gut microbiome in psoriasis is perturbed differently during secukinumab and ustekinumab therapy and associated with response to treatment.Clin Drug Investig2019;39:1195-203

[154] Critch J,Otley A,Teitelbaum JE.Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease.J Pediatr Gastroenterol Nutr2012;54:298-305

[155] Adamji M.An overview of the role of exclusive enteral nutrition for complicated Crohn’s disease.Intest Res2019;17:171-6 PMCID:PMC6505086

[156] Ruemmele FM,Kolho KL.Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease.J Crohns Colitis2014;8:1179-207

[157] Gatti S,Franceschini E.Effects of the exclusive enteral nutrition on the microbiota profile of patients with Crohn’s disease: a systematic review.Nutrients2017;9:832 PMCID:PMC5579625

[158] MacLellan A,Grant S,Langille MGI.The impact of exclusive enteral nutrition (EEN) on the gut microbiome in Crohn’s disease: a review.Nutrients2017;9:0447 PMCID:PMC5452177

[159] Melton SL,Gibson PR.Review article: Mechanisms underlying the effectiveness of exclusive enteral nutrition in Crohn’s disease.Aliment Pharmacol Ther2023;57:932-47

[160] Horwat P,Garczyk A.Influence of enteral nutrition on gut microbiota composition in patients with Crohn’s disease: a systematic review.Nutrients2020;12:2551 PMCID:PMC7551474

[161] Diederen K,Donachie GE.Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn’s disease.Sci Rep2020;10:18879 PMCID:PMC7609694

[162] Quince C,Loman N.Extensive modulation of the fecal metagenome in children with Crohn’s disease during exclusive enteral nutrition.Am J Gastroenterol2015;110:1718-29 PMCID:PMC4697132

[163] Lv Y,Liu A.The impact of exclusive enteral nutrition on the gut microbiome and bile acid metabolism in pediatric Crohn’s disease.Clin Nutr2023;42:116-28

[164] Jones CMA,Dunn KA.Bacterial taxa and functions are predictive of sustained remission following exclusive enteral nutrition in pediatric Crohn’s disease.Inflamm Bowel Dis2020;26:1026-37 PMCID:PMC7301407

[165] Xiao F,Hu H.Exclusive enteral nutrition exerts anti-inflammatory effects through modulating microbiota, bile acid metabolism, and immune activities.Nutrients2022;14:4463 PMCID:PMC9657881

[166] Jiang J,Chen Y.Exclusive enteral nutrition remodels the intestinal flora in patients with active Crohn’s disease.BMC Gastroenterol2022;22:212 PMCID:PMC9059691

[167] Dunn KA,MacIntyre B.Early changes in microbial community structure are associated with sustained remission after nutritional treatment of pediatric Crohn’s disease.Inflamm Bowel Dis2016;22:2853-62

[168] Salem GA.Stem cell transplant in inflammatory bowel disease: a promising modality of treatment for a complicated disease course.Stem Cell Investig2017;4:95 PMCID:PMC5723741

[169] Kavanagh DPJ.Hematopoietic stem cell homing to injured tissues.Stem Cell Rev Rep2011;7:672-82

[170] Zhang HM,Meng H.Stem cell-based therapies for inflammatory bowel disease.Int J Mol Sci2022;23:8494 PMCID:PMC9368934

[171] Brierley CK,Labopin M.Autologous haematopoietic stem cell transplantation for Crohn’s disease: a retrospective survey of long-term outcomes from the european society for blood and marrow transplantation.J Crohns Colitis2018;12:1097-103 PMCID:PMC6113702

[172] Zama D,Masetti R.Gut microbiota and hematopoietic stem cell transplantation: where do we stand?.Bone Marrow Transplant2017;52:7-14

[173] Ono S,Kiridoshi Y.Hematopoietic cell transplantation rescues inflammatory bowel disease and dysbiosis of gut microbiota in XIAP deficiency.J Allergy Clin Immunol Pract2021;9:3767-80

[174] Metwaly A,Waldschmitt N.Integrated microbiota and metabolite profiles link Crohn’s disease to sulfur metabolism.Nat Commun2020;11:4322 PMCID:PMC7456324

[175] Okamoto R.Investigating cell therapy for inflammatory bowel disease.Expert Opin Biol Ther2016;16:1015-23

[176] Bieback K. Isolation, culture, and characterization of human umbilical cord blood-derived mesenchymal stromal cells. In: Gnecchi M, editor. Mesenchymal stem cells. New York: Springer; 2016. p. 245-58. Available from: http://link.springer.com/10.1007/978-1-4939-3584-0_14. [Last accessed 25 Sep 2023]

[177] Pittenger MF,Beck SC.Multilineage potential of adult human mesenchymal stem cells.Science1999;284:143-7

[178] Stappenbeck TS.The role of stromal stem cells in tissue regeneration and wound repair.Science2009;324:1666-9

[179] Ocansey DKW,Wang J.Mesenchymal stem cell-gut microbiota interaction in the repair of inflammatory bowel disease: an enhanced therapeutic effect.Clin Transl Med2019;8:31 PMCID:PMC6928179

[180] Forbes GM,Leong RW.A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn’s disease refractory to biologic therapy.Clin Gastroenterol Hepatol2014;12:64-71

[181] Dhere T,Garcia M.The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn’s disease - a phase 1 trial with three doses.Aliment Pharmacol Ther2016;44:471-81

[182] Zhang J,Liu X,Shi L.Umbilical cord mesenchymal stem cell treatment for Crohn’s disease: a randomized controlled clinical trial.Gut Liver2018;12:73-8 PMCID:PMC5753687

[183] Hu J,Zhang L.Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis.Exp Ther Med2016;12:2983-9 PMCID:PMC5103734

[184] Lazebnik LB,Konopliannikov AG.[Allogeneic mesenchymal stromal cells in patients with ulcerative colitis: two years of observation].Eksp Klin Gastroenterol2010;11:3-15.

[185] Lazebnik LB,Parfenov AI,Rogozina VA.[Transplantation of allogeneic mesenchymal stem cells from the bone marrow increases duration of remission and reduces the risk of ulcerative colitis relapse].Eksp Klin Gastroenterol2010;3:5-10.

[186] Saadh MJ,Rasoolzadegan S.Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy.Eur J Med Res2023;28:47 PMCID:PMC9881387

[187] Soontararak S,Johnson V.Mesenchymal stem cells (MSC) derived from induced pluripotent stem cells (iPSC) equivalent to adipose-derived msc in promoting intestinal healing and microbiome normalization in mouse inflammatory bowel disease model.Stem Cells Transl Med2018;7:456-67 PMCID:PMC5980202

[188] He R,Li Y,Hou X.Cancer-preventive role of bone marrow-derived mesenchymal stem cells on colitis-associated colorectal cancer: roles of gut microbiota involved.Front Cell Dev Biol2021;9:642948 PMCID:PMC8212064

[189] Yang F,Liu Q.Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota.Stem Cell Res Ther2022;13:475 PMCID:PMC9476645

[190] Yang F,Liang W.Short-term clinical response and changes in the fecal microbiota and metabolite levels in patients with Crohn’s disease after stem cell infusions.Stem Cells Transl Med2023;12:497-509 PMCID:PMC10427961

[191] Wang A,Ding Q.Intestinal Cetobacterium and acetate modify glucose homeostasis via parasympathetic activation in zebrafish.Gut Microbes2021;13:1-15 PMCID:PMC8043178

[192] Xie M,Li Y.Stabilized fermentation product of Cetobacterium somerae improves gut and liver health and antiviral immunity of zebrafish.Fish Shellfish Immunol2022;120:56-66

[193] Cui B,Xu L.Step-up fecal microbiota transplantation (FMT) strategy.Gut Microbes2016;7:323-8 PMCID:PMC4988439

[194] Cui B,Xu L.Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis.J Transl Med2015;13:298 PMCID:PMC4567790

[195] Ding X,Li P.Long-term safety and efficacy of fecal microbiota transplant in active ulcerative colitis.Drug Saf2019;42:869-80

[196] Xiang L,Li Q.Efficacy of faecal microbiota transplantation in Crohn’s disease: a new target treatment?.Microb Biotechnol2020;13:760-9 PMCID:PMC7111085

[197] Park SK,Kim SS.Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis.Korean J Intern Med2022;37:949-57 PMCID:PMC9449212

[198] Tursi A,Papa A.Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.Am J Gastroenterol2010;105:2218-27 PMCID:PMC3180711

[199] Peng L,Wang A.Probiotics combined with aminosalicylic acid affiliates remission of ulcerative colitis: a meta-analysis of randomized controlled trial.Biosci Rep2019;39:BSR20180943 PMCID:PMC6340951

[200] Rooks MG,Wardwell-Scott LH.Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission.ISME J2014;8:1403-17 PMCID:PMC4069400